<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815566</url>
  </required_header>
  <id_info>
    <org_study_id>IN-CA-311-3963</org_study_id>
    <nct_id>NCT02815566</nct_id>
  </id_info>
  <brief_title>Bone Health in Aging HIV Infected Women</brief_title>
  <acronym>BEING</acronym>
  <official_title>Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Raffaele University Hospital, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Design: Open-label randomised multicenter international strategic trial of older women on&#xD;
      combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with&#xD;
      HIV RNA suppression for &gt; 6 months to : 1. Immediate switch of TDF/FTC to tenofovir&#xD;
      alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2.&#xD;
      Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third&#xD;
      agent. Follow up of all subjects to 96 weeks.&#xD;
&#xD;
      Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years&#xD;
      (peri or early post menopause). .&#xD;
&#xD;
      Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar&#xD;
      spine at weeks 48 and 96.&#xD;
&#xD;
      Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by&#xD;
      high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality,&#xD;
      geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral&#xD;
      suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96.&#xD;
&#xD;
      Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree&#xD;
      correlating with a decreased risk of fragility fracture in aging HIV infected women.&#xD;
      Secondary outcomes will assess bone strength using new imaging modalities, timing of switch,&#xD;
      and renal health. This data will be used by health policy makers and providers to determine&#xD;
      the proper use of TAF/FTC in the aging HIV population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized controlled clinical trial (RCT) of immediate vs delayed switch from TDF/FTC to&#xD;
      TAF/FTC to define the impact of switching ARV on BMD in different stages of the aging&#xD;
      trajectory in HIV infected women. Included is a geriatric assessment based on the&#xD;
      conceptualization of health transition across menopause.&#xD;
&#xD;
      Study Hypothesis: The primary hypothesis is that switching from TDF/FTC will improve BMD to a&#xD;
      degree that correlates with a lower fracture risk in aging HIV+ women. We will further&#xD;
      explore our theory that the impact is greater in those in the early stages of menopause and&#xD;
      in those who also receive a protease inhibitor (PI) as the third antiretroviral agent (ARV).&#xD;
&#xD;
      Primary objectives: To determine if: 1. Switching HIV+ women on TDF/FTC to TAF/FTC increases&#xD;
      BMD at the spine at 48 weeks relative to those who continue TDF/FTC 2. To determine if any&#xD;
      observed improvements continue or stabilize in the year after switch.&#xD;
&#xD;
      Hypothesis generating objectives: To determine if the effect of switching from TDF/FTC to&#xD;
      TAF/FTC on BMD varies by stage of menopause and by third ARV.&#xD;
&#xD;
      Study design: This study is double blind placebo controlled randomised, 1:1, multicentre&#xD;
      strategic trial. Patients will be randomised to immediate vs delayed switch, with&#xD;
      randomization allocation arranged to minimize differences between treatment group with&#xD;
      respect to stage of menopause (peri- menopause vs early post menopause) and site. Study&#xD;
      population: HIV positive women who are in the peri-menopausal period or those within 10 years&#xD;
      post menopause to capture those with greatest risk of BMD loss. As menopause typically occurs&#xD;
      earlier in HIV + women we include those aged 45-55 years. They must be on a cART regimen&#xD;
      containing TDF/FTC with HIV RNA &lt;50 c/ml for at least 6 months.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
        1. Immediate switch of TDF/FTC to TAF/FTC while maintaining the third ARV agent.&#xD;
&#xD;
        2. Delayed switch of TDF/FTC to TAF/FTC at 48 weeks while maintaining the third ARV agent.&#xD;
&#xD;
      Randomization: A computer-generated randomization list will be prepared prior to study onset&#xD;
      by a statistician unassociated with the study. Randomization will be stratified by study&#xD;
      centre.&#xD;
&#xD;
      Primary endpoint: Comparison of the immediate vs delayed group in the % change from baseline&#xD;
      in BMD at the lumbar spine at week 48 and 96.&#xD;
&#xD;
      Secondary endpoints: Will compare changes between the immediate and delayed group from data&#xD;
      collected at screening or baseline and weeks 48 and 96.&#xD;
&#xD;
        -  change from baseline in BMD at hip Changes in Bone architecture as determined by&#xD;
           Trabecular bone scan (TBS) and HRpQCT (high resolution peripheral quantitative&#xD;
           computerized tomography) (Toronto site) Changes in 10 year fracture risk determined by&#xD;
           country specific FRAXÂ® (fracture risk assessment) calculator&#xD;
&#xD;
        -  with HIV-1 RNA &lt;50 c/ml Change from baseline in geriatric functional measures: frailty,&#xD;
           performance and balance Change from baseline in muscle quality: Sarcopenia - grip&#xD;
           strength measured by a Dynamometer Change from baseline in lipid values and Framingham&#xD;
           cardiovascular risk scores Changes in renal tubular and glomerular function: GFR&#xD;
           (glomerular filtration rate), Creatinine, urine albumin /creatinine and&#xD;
           protein/creatinine, glucosuria Safety (clinical and laboratory adverse events) Changes&#xD;
           in biomarkers of inflammation, coagulation and bone metabolism Tolerability (EuroQoL&#xD;
           questionnaire)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>per cent change in bone mineral density from baseline at the lumbar spine</measure>
    <time_frame>48 weeks and 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change in bone mineral density from baseline at the hip</measure>
    <time_frame>48 weeks and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral load</measure>
    <time_frame>24, 48 and 96 weeks</time_frame>
    <description>proportion who maintain suppression to &lt; 50 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in bone architecture</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>measured by HRqCT (high resolution quantitative computerized tomography), and trabecular bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>change in glomerular filtration rate, and proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sarcopenia</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>change in grip strength using a dynameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fall frequency</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>changes in self administered questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>balance and walking speed</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>changes in short performance physical battery test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frailty</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>changes in frailty index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholesterol</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>changes in low density lipoprotein cholesterol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Osteoporosis</condition>
  <condition>HIV</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Immediate switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>delayed switch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir-alafenamide-emtricitabine</intervention_name>
    <description>comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density</description>
    <arm_group_label>Immediate switch</arm_group_label>
    <other_name>Descovy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir-emtricitabine</intervention_name>
    <description>comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density</description>
    <arm_group_label>delayed switch</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biological female aged 40-60&#xD;
&#xD;
          2. Documented HIV-1 infection&#xD;
&#xD;
          3. Peri-menopausal ( as documented by history).&#xD;
&#xD;
          4. Signed Informed Consent Form and willing to comply with the protocol.&#xD;
&#xD;
          5. Receiving a cART regimen containing a ritonavir boosted PI (darunavir, atazanavir,&#xD;
             lopinavir,) or an NNRTI (efavirenz, nevirapine or rilpivirine) or an integrase&#xD;
             inhibitor (dolutegravir or raltegravir or elvitegravir) in combination with TDF-FTC&#xD;
             for &gt; 24 weeks.&#xD;
&#xD;
          6. Stable viral suppression (plasma HIV-RNA&lt;50 copies/mL for &gt; 24 weeks). Single viral&#xD;
             blip &lt;500/ml allowed if re-suppresses.&#xD;
&#xD;
          7. If of childbearing potential, is using effective birth control methods and is willing&#xD;
             to continue during the trial.&#xD;
&#xD;
          8. Women will be assessed for vitamin D and calcium dietary intake; if inadequate for&#xD;
             age, supplements will be recommended.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HIV-2&#xD;
&#xD;
          2. High 10-year fracture risk at baseline ( &gt; 20%) based on country specific FRAX&#xD;
&#xD;
          3. Current treatment with active bone medications- bisphosphonates, denosumab,&#xD;
             calcitonin, raloxifene, teriparatide, strontium&#xD;
&#xD;
          4. Current use of systemic steroids ( inhaled steroids permitted) or chemotherapeutic&#xD;
             agents&#xD;
&#xD;
          5. Acute viral hepatitis&#xD;
&#xD;
          6. Chronic hepatitis C with liver transaminases &gt;5 x ULN or expected to require treatment&#xD;
             for hepatitis C during the trial period.&#xD;
&#xD;
          7. Any investigational ARV within 30 days.&#xD;
&#xD;
          8. Dialysis or renal insufficiency (creatinine clearance &lt; 50ml/min)&#xD;
&#xD;
          9. History of decompensated liver disease (AST or ALTâ¥5x the upper limit of normal (ULN)&#xD;
             or ALT â¥ 3 x ULN and bilirubin â¥ 1.5 x ULN with &gt; 35% direct bilirubin), or the&#xD;
             presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or&#xD;
             gastric varices.&#xD;
&#xD;
         10. Pregnant or breastfeeding&#xD;
&#xD;
         11. Screening blood result with any grade 3/4 toxicity according to Division of AIDS&#xD;
             (DAIDS) grading scale, except: asymptomatic grade 3 amylase, creatinine phosphokinase,&#xD;
             or lipid elevation.&#xD;
&#xD;
         12. Any condition (including illicit drug use or alcohol abuse) or lab results which, in&#xD;
             the investigator's opinion, interfere with assessments or completion of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sharon walmsley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de QuÃ©bec-UniversitÃ© Laval</name>
      <address>
        <city>QuÃ©bec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Modena e Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Sharon Walmsley, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>kidney, antiretroviral agent, tenofovir, osteoporosis, women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information on viral load, toxicity and bone scans will be available to treating physicians</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

